Bifogade filer
PDF
Kurs & Likviditet
Kalender
| 2024-10-24 | Kvartalsrapport 2024-Q3 |
| 2024-07-18 | Kvartalsrapport 2024-Q2 |
| 2024-06-28 | Ordinarie utdelning HNSA 0.00 SEK |
| 2024-06-27 | Årsstämma 2024 |
| 2024-04-18 | Kvartalsrapport 2024-Q1 |
| 2024-02-02 | Bokslutskommuniké 2023 |
| 2023-10-26 | Kvartalsrapport 2023-Q3 |
| 2023-07-20 | Kvartalsrapport 2023-Q2 |
| 2023-06-15 | Ordinarie utdelning HNSA 0.00 SEK |
| 2023-06-14 | Årsstämma 2023 |
| 2023-04-20 | Kvartalsrapport 2023-Q1 |
| 2023-02-02 | Bokslutskommuniké 2022 |
| 2022-10-20 | Kvartalsrapport 2022-Q3 |
| 2022-07-19 | Kvartalsrapport 2022-Q2 |
| 2022-06-17 | Ordinarie utdelning HNSA 0.00 SEK |
| 2022-06-16 | Årsstämma 2022 |
| 2022-04-21 | Kvartalsrapport 2022-Q1 |
| 2022-02-03 | Bokslutskommuniké 2021 |
| 2021-10-21 | Kvartalsrapport 2021-Q3 |
| 2021-07-15 | Kvartalsrapport 2021-Q2 |
| 2021-05-14 | Ordinarie utdelning HNSA 0.00 SEK |
| 2021-05-12 | Årsstämma 2021 |
| 2021-04-22 | Kvartalsrapport 2021-Q1 |
| 2021-02-04 | Bokslutskommuniké 2020 |
| 2020-10-22 | Kvartalsrapport 2020-Q3 |
| 2020-07-16 | Kvartalsrapport 2020-Q2 |
| 2020-06-24 | Ordinarie utdelning HNSA 0.00 SEK |
| 2020-06-23 | Årsstämma 2020 |
| 2020-04-28 | Kvartalsrapport 2020-Q1 |
| 2020-02-06 | Bokslutskommuniké 2019 |
| 2019-10-31 | Kvartalsrapport 2019-Q3 |
| 2019-07-18 | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | Ordinarie utdelning HNSA 0.00 SEK |
| 2019-05-22 | Årsstämma 2019 |
| 2019-04-29 | Kvartalsrapport 2019-Q1 |
| 2019-02-08 | Bokslutskommuniké 2018 |
| 2018-11-01 | Kvartalsrapport 2018-Q3 |
| 2018-07-19 | Kvartalsrapport 2018-Q2 |
| 2018-05-30 | Ordinarie utdelning HNSA 0.00 SEK |
| 2018-05-29 | Årsstämma 2018 |
| 2018-04-25 | Kvartalsrapport 2018-Q1 |
| 2018-02-14 | Bokslutskommuniké 2017 |
| 2017-12-22 | Extra Bolagsstämma 2017 |
| 2017-11-14 | Kvartalsrapport 2017-Q3 |
| 2017-07-20 | Kvartalsrapport 2017-Q2 |
| 2017-05-24 | Ordinarie utdelning HNSA 0.00 SEK |
| 2017-05-23 | Årsstämma 2017 |
| 2017-04-26 | Kvartalsrapport 2017-Q1 |
| 2017-02-15 | Bokslutskommuniké 2016 |
| 2016-11-21 | Extra Bolagsstämma 2016 |
| 2016-11-09 | Kvartalsrapport 2016-Q3 |
| 2016-07-21 | Kvartalsrapport 2016-Q2 |
| 2016-05-11 | Årsstämma 2016 |
| 2016-04-28 | Ordinarie utdelning HNSA 0.00 SEK |
| 2016-04-27 | Kvartalsrapport 2016-Q1 |
| 2016-02-18 | Bokslutskommuniké 2015 |
| 2015-10-28 | Kvartalsrapport 2015-Q3 |
| 2015-08-25 | Kvartalsrapport 2015-Q2 |
| 2015-04-17 | Ordinarie utdelning HNSA 0.00 SEK |
| 2015-04-16 | Årsstämma 2015 |
| 2015-04-16 | Kvartalsrapport 2015-Q1 |
| 2015-02-05 | Bokslutskommuniké 2014 |
| 2014-07-25 | Kvartalsrapport 2014-Q2 |
| 2014-06-04 | Ordinarie utdelning HNSA 0.00 SEK |
| 2014-06-03 | Årsstämma 2014 |
| 2014-03-05 | Extra Bolagsstämma 2014 |
| 2014-02-05 | Bokslutskommuniké 2013 |
| 2013-07-25 | Kvartalsrapport 2013-Q2 |
| 2013-05-07 | Ordinarie utdelning HNSA 0.00 SEK |
| 2013-05-06 | Årsstämma 2013 |
| 2013-02-07 | Bokslutskommuniké 2012 |
| 2012-09-28 | Kapitalmarknadsdag 2012 |
| 2012-07-26 | Kvartalsrapport 2012-Q2 |
| 2012-05-14 | Årsstämma 2012 |
| 2012-02-09 | Bokslutskommuniké 2011 |
| 2012-01-09 | Extra Bolagsstämma 2011 |
| 2011-07-28 | Kvartalsrapport 2011-Q2 |
| 2011-05-12 | Årsstämma 2011 |
| 2011-05-06 | Ordinarie utdelning HNSA 0.00 SEK |
| 2010-04-30 | Ordinarie utdelning HNSA 0.00 SEK |
| 2010-02-10 | Bokslutskommuniké 2009 |
| 2009-07-30 | Kvartalsrapport 2009-Q1 |
| 2009-05-12 | Kvartalsrapport 2009-Q2 |
| 2009-04-30 | Ordinarie utdelning HNSA 0.00 SEK |
| 2009-04-29 | Årsstämma 1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Lund May 25, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the ongoing EMA review of imlifidase for a potential marketing authorization in Europe is on track. A CHMP opinion is expected at the June 22-25 meeting, followed by a decision by the European Commission in Q3 2020.
At the CHMP meeting on April 28-30 a list of outstanding issues was adopted, including definition of patient population and design of the post approval study. A one-month clock-stop was initiated to enable Hansa Biopharma to address the outstanding issues. The Company will submit a comprehensive response on May 26 and expect an opinion from CHMP following the June 22-25 meeting.
"The EMA review process is progressing in line with our previous guidance. Throughout the process, we have had a positive and constructive dialouge with EMA and we look forward to an opinion from the CHMP in June", says Søren Tulstrup, President and CEO of Hansa Biopharma. "If approved, imlifidase has the potential to enable lifesaving kidney transplants in highly sensitized patients, who currently cannot receive this standard of care treatment."
The Marketing Authorization Application for imlifidase in kidney transplantation was accepted for review by the European Medicines Agency on Feb. 28, 2019.
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
Mobile: +46 (0) 709-298 269
E-mail: